The ADC binds TROP2 on tumor cells, is internalized, and releases the tirumotecan payload, which inhibits topoisomerase I to cause DNA damage and apoptosis; killing is driven by TROP2 targeting (with possible bystander effect), not by topoisomerase I expression alone.